Latest News & Updates of Loncom Pharma

NMPA's July 2026 announcement specifies four scenarios for chemical API priority review, effective 1 August.

Bestcomm won "Independent Innovation Enterprise" and "Top 50 R&D Company" at the 2025–2026 Industry Conference.

ICH E6(R3) Annex 2 provides GCP guidance for decentralised, pragmatic, and RWD‑enriched trials. It emphasises proportionality, QbD, patient engagement, and early regulator dialogue, reshaping clinical trial quality management for the digital era.

Bestcomm Pharmaceutical has been named among the 2026 Top 20 Chinese Pharmaceutical CRO Enterprises by the PDI Summit. The ranking evaluates revenue, R&D investment, headcount, brand awareness, and more. As a leading one‑stop R&D solution provider, Bestcomm is committed to accelerating innovative drug development and delivering high‑quality therapies to patients.